PICO Portalanswers from OpenAlex
The Netherlands Cancer Institute
InstitutionResearch output, impact & collaborations
The Netherlands Cancer Institute is a institution indexed in PICO Portal from OpenAlex.
What is known about The Netherlands Cancer Institute?
PICO Portalrecord summary
The Netherlands Cancer Institute is a research organisation in Amsterdam, NL. OpenAlex records 29,793 works and 5,742,475 citations for it. 5,422 researchers list it as their most recent affiliation.
How many works does The Netherlands Cancer Institute have?
PICO Portalindexed works
The Netherlands Cancer Institute has 29,793 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does The Netherlands Cancer Institute have?
PICO Portalcitation count
The Netherlands Cancer Institute has 5,742,475 citations in the OpenAlex counts PICO Portal stores.
How many researchers are at The Netherlands Cancer Institute?
PICO Portalresearcher count
The Netherlands Cancer Institute has 5,422 researchers in the PICO Portal index.
What is the average h-index at The Netherlands Cancer Institute?
PICO Portalavg h-index
The Netherlands Cancer Institute has an average h-index of 69.3 in OpenAlex.
What is the ROR of The Netherlands Cancer Institute?
PICO Portalror
The ROR for The Netherlands Cancer Institute is on the source record.
What is the OpenAlex record for The Netherlands Cancer Institute?
PICO Portalopenalex
The OpenAlex for The Netherlands Cancer Institute is on the source record.
Who are the most-cited researchers behind The Netherlands Cancer Institute?
PICO Portaltop researchers by citations
What are the most-cited papers on The Netherlands Cancer Institute?
PICO Portalmost cited works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa Ho, Martin L. Miller, Natasha Rekhtman, André L. Moreira, Fawzia K. Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer
Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries
Barbara Gandek, John E. Ware, Neil K. Aaronson, Giovanni Apolone, Jakob Bue Bjørner, John Brazier, Monika Bullinger, Stein Kaasa, Alain Leplège, Luis Prieto, Marianne Sullivan
Risks of Breast, Ovarian, and Contralateral Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers
Karoline Kuchenbaecker, John L. Hopper, Daniel R. Barnes, Kelly‐Anne Phillips, Thea M. Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E. van Leeuwen, Roger L. Milne, Nadine Andrieu, David E. Goldgar, Mary Beth Terry, Matti A. Rookus, Douglas F. Easton, Antonis C. Antoniou, Lesley McGuffog, D. Gareth Evans, Daniel Barrowdale, Debra Frost, Julian Adlard, Kai-Ren Ong, Louise Izatt, Marc Tischkowitz, Rosalind A. Eeles, Rosemarie Davidson, Shirley Hodgson, Steve Ellis, Catherine Noguès, Christine Lasset, Dominique Stoppa‐Lyonnet, Jean‐Pierre Fricker, Laurence Faivre, Pascaline Berthet, Maartje J. Hooning, Lizet E. van der Kolk, Carolien M. Kets, Muriel A. Adank, Esther M. John, Wendy K. Chung, Irene L. Andrulis, Melissa C. Southey, Mary B. Daly, Saundra S. Buys, Ana Osório, Christoph Engel, Karin Kast, Rita K. Schmutzler, Trinidad Caldés, Anna Jakubowska, Jacques Simard, Michael Friedländer, Sue‐Anne McLachlan, Eva Macháčková, Lenka Foretová, Yen Y. Tan, Christian F. Singer, Edith Oláh, Anne‐Marie Gerdes, Brita Arver, Håkan Olsson
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
Who collaborates most closely around The Netherlands Cancer Institute?
PICO Portalco-authorship network
United States
29%
Germany
29%
Netherlands
14%
France
14%
United Kingdom
14%
How much of the research on The Netherlands Cancer Institute is open access?
PICO Portalopen access share
42%OPEN ACCESS